SMA 200 společnosti Acelrx Pharmaceuticals Inc
Jaká je hodnota metriky SMA 200 společnosti Acelrx Pharmaceuticals Inc?
Hodnota metriky SMA 200 společnosti Acelrx Pharmaceuticals Inc je $1 -49.46%
Jaká je definice metriky SMA 200?
SMA 200 je průměrná cena akcií z posledních 200 dnů vypočítaná jako nevážený průměr předchozích 200 závěrečných cen.
Simple moving average of 200 days for a stock is an unweighted moving average over the past 200 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
SMA 200 společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Acelrx Pharmaceuticals Inc
Čemu se věnuje společnost Acelrx Pharmaceuticals Inc?
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Firmy s metrikou sma 200 podobnou společnosti Acelrx Pharmaceuticals Inc
- Hodnota metriky SMA 200 společnosti Opko Health Inc je $1 +17.86%
- Hodnota metriky SMA 200 společnosti Fullsun International Co je HKD$1 -36.39%
- Hodnota metriky SMA 200 společnosti CYBERDYNE je $1 +7.07%
- Hodnota metriky SMA 200 společnosti Galecto je $1 +90.22%
- Hodnota metriky SMA 200 společnosti Dbt Sa je €1 -91.33%
- Hodnota metriky SMA 200 společnosti Rifco je CAD$1 -1.18%
- Hodnota metriky SMA 200 společnosti Acelrx Pharmaceuticals Inc je $1 -49.46%
- Hodnota metriky SMA 200 společnosti Societe de Tayninh SA je €1 -6.49%
- Hodnota metriky SMA 200 společnosti Clearside Biomedical Inc je $1 +1.63%
- Hodnota metriky SMA 200 společnosti Rusoro Mining je CAD$1 +0.82%
- Hodnota metriky SMA 200 společnosti Fox Marble PLC je GBX1 +4.44%
- Hodnota metriky SMA 200 společnosti Ping An Healthcare and Technology je $1 -31.96%
- Hodnota metriky SMA 200 společnosti Future Generation Global Investment je AUD$1 +2.82%